ATE313557T1 - Modifiziertes, als medikamentvorstufe anwendbares cyclosporin und dessen verwendung - Google Patents

Modifiziertes, als medikamentvorstufe anwendbares cyclosporin und dessen verwendung

Info

Publication number
ATE313557T1
ATE313557T1 AT02713992T AT02713992T ATE313557T1 AT E313557 T1 ATE313557 T1 AT E313557T1 AT 02713992 T AT02713992 T AT 02713992T AT 02713992 T AT02713992 T AT 02713992T AT E313557 T1 ATE313557 T1 AT E313557T1
Authority
AT
Austria
Prior art keywords
predrug
modified
cyclosporine used
modified cyclosporine
pro
Prior art date
Application number
AT02713992T
Other languages
English (en)
Inventor
Roland Wenger
Manfred Mutter
Arnaud Hamel
Francis Hubler
Original Assignee
Debiopharm Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Debiopharm Sa filed Critical Debiopharm Sa
Application granted granted Critical
Publication of ATE313557T1 publication Critical patent/ATE313557T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT02713992T 2001-04-20 2002-04-22 Modifiziertes, als medikamentvorstufe anwendbares cyclosporin und dessen verwendung ATE313557T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH7202001 2001-04-20
PCT/CH2002/000222 WO2002085928A2 (fr) 2001-04-20 2002-04-22 Cyclosporine modifiee utilisable en tant que pro-drogue et son utilisation

Publications (1)

Publication Number Publication Date
ATE313557T1 true ATE313557T1 (de) 2006-01-15

Family

ID=4531478

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02713992T ATE313557T1 (de) 2001-04-20 2002-04-22 Modifiziertes, als medikamentvorstufe anwendbares cyclosporin und dessen verwendung

Country Status (17)

Country Link
US (1) US6995139B2 (de)
EP (1) EP1379547B1 (de)
JP (1) JP4588979B2 (de)
KR (1) KR100932859B1 (de)
CN (1) CN1507451A (de)
AT (1) ATE313557T1 (de)
AU (1) AU2002245996B8 (de)
BR (1) BR0208923A (de)
CA (1) CA2444278C (de)
DE (1) DE60208180T2 (de)
ES (1) ES2256450T3 (de)
IL (1) IL158385A0 (de)
MX (1) MXPA03009586A (de)
RU (1) RU2290196C2 (de)
UA (1) UA75136C2 (de)
WO (1) WO2002085928A2 (de)
ZA (1) ZA200307794B (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7232924B2 (en) 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7354574B2 (en) 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
WO2004082629A2 (en) 2003-03-17 2004-09-30 Albany Molecular Research, Inc. Novel cyclosporins
US7087237B2 (en) 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
US7083803B2 (en) 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
US20110104186A1 (en) 2004-06-24 2011-05-05 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
JP2008514702A (ja) 2004-09-29 2008-05-08 エーエムアール テクノロジー インコーポレイテッド 新規シクロスポリン類似体およびそれらの薬学的使用
US7378391B2 (en) 2004-09-29 2008-05-27 Amr Technology, Inc. Cyclosporin alkyne analogues and their pharmaceutical uses
US7361636B2 (en) 2004-10-06 2008-04-22 Amr Technology, Inc. Cyclosporin alkynes and their utility as pharmaceutical agents
EP1904056B1 (de) 2005-07-18 2009-04-29 Minu, L.L.C. Verwendung von Makroliden zur Wiederherstellung der Kornealempfindungen
US7696165B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
US7696166B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
WO2008013860A2 (en) * 2006-07-28 2008-01-31 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of alpha-amino acids, methods of synthesis and use
US8394763B2 (en) 2007-09-26 2013-03-12 Oregon Health & Science University Cyclic undecapeptides and derivatives as multiple sclerosis therapies
WO2009098533A1 (en) * 2008-02-08 2009-08-13 Debiopharm Sa Non -immunosuppressive cyclosporin for the treatment of muscular dystrophy
GB0912584D0 (en) * 2009-07-20 2009-08-26 Ucl Business Plc Cyclosporin conjugates
KR102011339B1 (ko) 2010-12-15 2019-08-16 콘트라빌 파마슈티컬스, 인코퍼레이티드 아미노산 1 및 3에서 변형된 사이클로스포린 유사체 분자
AR090964A1 (es) * 2012-05-09 2014-12-17 Novartis Ag Proceso para la elaboracion de undecapeptidos ciclicos
CN113388002A (zh) * 2021-06-10 2021-09-14 梯尔希（南京）药物研发有限公司 一种环孢菌素相关化合物的制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0098456B1 (de) * 1980-02-14 1989-05-24 Sandoz Ag Peptide die einen (1S,2R,3R)- oder (1R,2S,3S)-1-Nitrilo-1-carbonyl-3-methyl-2-oxyheptan oder -hept-5-en-Rest enthalten brauchbar in totaler Synsthese von Cyclosporinen, und Verfahren zu ihrer Herstellung
US4396542A (en) * 1980-02-14 1983-08-02 Sandoz Ltd. Method for the total synthesis of cyclosporins, novel cyclosporins and novel intermediates and methods for their production
US5169773A (en) * 1984-10-04 1992-12-08 Sandoz Ltd. Monoclonal antibodies to cyclosporins
EP0177654B1 (de) * 1984-10-10 1989-05-31 Societe D'etudes Scientifiques Et Industrielles De L'ile-De-France Synergistische empfängnisverhütende Mischung
US4764503A (en) * 1986-11-19 1988-08-16 Sandoz Ltd. Novel cyclosporins
GB8717300D0 (en) * 1987-07-22 1987-08-26 Nat Res Dev Cyclosporins
HU201577B (en) * 1988-12-20 1990-11-28 Gyogyszerkutato Intezet Process for producing cyclosporin antibiotics
GB9116836D0 (en) * 1991-08-05 1991-09-18 Sandoz Ltd Organic compounds
ES2095926T5 (es) * 1990-11-02 2001-02-16 Novartis Ag Cyclosporins.
GB9204466D0 (en) * 1992-03-02 1992-04-15 Sandoz Ltd Improvements in or relating to organic compounds
US6187547B1 (en) * 1993-09-08 2001-02-13 Novartis Ag Assay kit
GB9624038D0 (en) * 1996-11-19 1997-01-08 Sandoz Ltd Organic compounds
US6017879A (en) * 1998-04-03 2000-01-25 B.M.R.A. Corporation B.V. Template associated NPY Y2-receptor agonists
USRE40987E1 (en) 1998-07-01 2009-11-17 Debiopharm S.A. Cyclosporin with improved activity profile
US6204257B1 (en) * 1998-08-07 2001-03-20 Universtiy Of Kansas Water soluble prodrugs of hindered alcohols
DK1150999T3 (da) * 1999-02-05 2006-10-30 Debiopharm Sa Cyclosporinderivater og fremgangsmåde til fremstilling deraf
US6765019B1 (en) * 1999-05-06 2004-07-20 University Of Kentucky Research Foundation Permeable, water soluble, non-irritating prodrugs of chemotherapeutic agents with oxaalkanoic acids
WO2001005819A1 (en) * 1999-07-15 2001-01-25 Kuhnil Pharm. Co., Ltd. Novel water soluble-cyclosporine conjugated compounds
JP2003507438A (ja) * 1999-08-24 2003-02-25 セルゲイト， インコーポレイテッド オリゴアルギニン部分を使用する上皮組織を横切るおよび上皮組織内への薬物送達の増強

Also Published As

Publication number Publication date
MXPA03009586A (es) 2004-05-24
AU2002245996B8 (en) 2005-07-14
BR0208923A (pt) 2004-04-27
RU2290196C2 (ru) 2006-12-27
US20040138108A1 (en) 2004-07-15
CA2444278C (en) 2011-11-22
JP2004536051A (ja) 2004-12-02
CA2444278A1 (en) 2002-10-31
ES2256450T3 (es) 2006-07-16
AU2002245996B2 (en) 2005-06-30
EP1379547B1 (de) 2005-12-21
WO2002085928A2 (fr) 2002-10-31
CN1507451A (zh) 2004-06-23
EP1379547A2 (de) 2004-01-14
UA75136C2 (en) 2006-03-15
RU2003133742A (ru) 2005-03-20
DE60208180T2 (de) 2006-08-17
DE60208180D1 (de) 2006-01-26
WO2002085928A3 (fr) 2003-04-17
KR100932859B1 (ko) 2009-12-23
JP4588979B2 (ja) 2010-12-01
US6995139B2 (en) 2006-02-07
ZA200307794B (en) 2004-07-19
IL158385A0 (en) 2004-05-12
KR20030094357A (ko) 2003-12-11

Similar Documents

Publication Publication Date Title
ATE313557T1 (de) Modifiziertes, als medikamentvorstufe anwendbares cyclosporin und dessen verwendung
EP4107180A4 (de) Designer-peptide und -proteine zur detektion, prävention und behandlung von coronavirus-krankheit 2019 (covid-19)
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
DE602007013391D1 (de) Cyclosporins zur behandlung und vorbeugung von augenerkrankungen
ATE300306T1 (de) Pharmazeutische zusammensetzung zur ophtalmologischen und rhinologischen anwendung
BR0116452A (pt) Composto, composição farmacêutica, uso de um composto
ATE455561T1 (de) Konjugate von zytotoxischen mitteln und biologisch aktiven peptiden
DE69938786D1 (de) Die verwendung von peptiden von il-2 und peptid-derivaten als therapeutische wirkstoffe
DE60331546D1 (de) Verwendung von aspartic proteasen in den bereichen kosmetik und behandlung
EA200500782A1 (ru) Лечение геморрагического шока
IL156774A0 (en) Inhibitors of cruzipain and other cysteine proteases
EP0932613A4 (de) Expressionsblockierung von virulenten faktoren in s. aureus
ATE330968T1 (de) Cyclosporin-derivate und verfahren zu deren herstellung
WO2003092632A3 (en) Cyclic peptide anti-cancer agents and methods
ATE479657T1 (de) N-(aryl)-2-arylethensulfonamide und ihre therapeutischen anwendungen
ATE554753T1 (de) 2,2'-dithio-bis(ethansulfonat) für den einsatz zur hemmung paclitaxel-induzierter abnormer thermoesthesia
HRP20031057B1 (hr) Tableta koja sadrži cetirizin i pseudoefedrin
DE60329115D1 (de) Tumorantigenprotein und dessen verwendung
DE69738600D1 (de) Neuroaktive peptide
HK1043534A1 (zh) 蛋白酶抑制剂
ATE433326T1 (de) Verwendung von löslichem fgl2 als immunosuppressivum
GB0221169D0 (en) Crystal
MXPA02009257A (es) Metodos y composiciones para elucidar perfiles de expresion de proteina en celulas.
EP1191096A4 (de) Neues protein und dessen dns
DE50206173D1 (de) Antiglaukomatoses mittel und dessen verwendung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties